516 related articles for article (PubMed ID: 33420027)
1. EGFR/SRC/ERK-stabilized YTHDF2 promotes cholesterol dysregulation and invasive growth of glioblastoma.
Fang R; Chen X; Zhang S; Shi H; Ye Y; Shi H; Zou Z; Li P; Guo Q; Ma L; He C; Huang S
Nat Commun; 2021 Jan; 12(1):177. PubMed ID: 33420027
[TBL] [Abstract][Full Text] [Related]
2. Monosomy of chromosome 10 associated with dysregulation of epidermal growth factor signaling in glioblastomas.
Yadav AK; Renfrow JJ; Scholtens DM; Xie H; Duran GE; Bredel C; Vogel H; Chandler JP; Chakravarti A; Robe PA; Das S; Scheck AC; Kessler JA; Soares MB; Sikic BI; Harsh GR; Bredel M
JAMA; 2009 Jul; 302(3):276-89. PubMed ID: 19602687
[TBL] [Abstract][Full Text] [Related]
3. Guanylate binding protein 1 is a novel effector of EGFR-driven invasion in glioblastoma.
Li M; Mukasa A; Inda MM; Zhang J; Chin L; Cavenee W; Furnari F
J Exp Med; 2011 Dec; 208(13):2657-73. PubMed ID: 22162832
[TBL] [Abstract][Full Text] [Related]
4. Role of glycosyltransferase PomGnT1 in glioblastoma progression.
Lan J; Guo P; Lin Y; Mao Q; Guo L; Ge J; Li X; Jiang J; Lin X; Qiu Y
Neuro Oncol; 2015 Feb; 17(2):211-22. PubMed ID: 25085363
[TBL] [Abstract][Full Text] [Related]
5. Functional genomics analyses of RNA-binding proteins reveal the splicing regulator SNRPB as an oncogenic candidate in glioblastoma.
Correa BR; de Araujo PR; Qiao M; Burns SC; Chen C; Schlegel R; Agarwal S; Galante PA; Penalva LO
Genome Biol; 2016 Jun; 17(1):125. PubMed ID: 27287018
[TBL] [Abstract][Full Text] [Related]
6. YTHDF2 suppresses cell proliferation and growth via destabilizing the EGFR mRNA in hepatocellular carcinoma.
Zhong L; Liao D; Zhang M; Zeng C; Li X; Zhang R; Ma H; Kang T
Cancer Lett; 2019 Feb; 442():252-261. PubMed ID: 30423408
[TBL] [Abstract][Full Text] [Related]
7. MYST1/KAT8 contributes to tumor progression by activating EGFR signaling in glioblastoma cells.
Dong Z; Zou J; Li J; Pang Y; Liu Y; Deng C; Chen F; Cui H
Cancer Med; 2019 Dec; 8(18):7793-7808. PubMed ID: 31691527
[TBL] [Abstract][Full Text] [Related]
8. An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway.
Guo D; Reinitz F; Youssef M; Hong C; Nathanson D; Akhavan D; Kuga D; Amzajerdi AN; Soto H; Zhu S; Babic I; Tanaka K; Dang J; Iwanami A; Gini B; Dejesus J; Lisiero DD; Huang TT; Prins RM; Wen PY; Robins HI; Prados MD; Deangelis LM; Mellinghoff IK; Mehta MP; James CD; Chakravarti A; Cloughesy TF; Tontonoz P; Mischel PS
Cancer Discov; 2011 Oct; 1(5):442-56. PubMed ID: 22059152
[TBL] [Abstract][Full Text] [Related]
9. Nuclear FABP7 immunoreactivity is preferentially expressed in infiltrative glioma and is associated with poor prognosis in EGFR-overexpressing glioblastoma.
Liang Y; Bollen AW; Aldape KD; Gupta N
BMC Cancer; 2006 Apr; 6():97. PubMed ID: 16623952
[TBL] [Abstract][Full Text] [Related]
10. ZC3H15 promotes glioblastoma progression through regulating EGFR stability.
Hou J; Xu M; Gu H; Pei D; Liu Y; Huang P; Chang H; Cui H
Cell Death Dis; 2022 Jan; 13(1):55. PubMed ID: 35027542
[TBL] [Abstract][Full Text] [Related]
11. LIN28A facilitates the transformation of human neural stem cells and promotes glioblastoma tumorigenesis through a pro-invasive genetic program.
Mao XG; Hütt-Cabezas M; Orr BA; Weingart M; Taylor I; Rajan AK; Odia Y; Kahlert U; Maciaczyk J; Nikkhah G; Eberhart CG; Raabe EH
Oncotarget; 2013 Jul; 4(7):1050-64. PubMed ID: 23846349
[TBL] [Abstract][Full Text] [Related]
12. Tyrphostin A9 attenuates glioblastoma growth by suppressing PYK2/EGFR-ERK signaling pathway.
Yadav N; Babu D; Madigubba S; Panigrahi M; Phanithi PB
J Neurooncol; 2023 Jul; 163(3):675-692. PubMed ID: 37415005
[TBL] [Abstract][Full Text] [Related]
13. EGFR-ERK pathway regulates CSN6 to contribute to PD-L1 expression in glioblastoma.
Su L; Guo W; Lou L; Nie S; Zhang Q; Liu Y; Chang Y; Zhang X; Li Y; Shen H
Mol Carcinog; 2020 May; 59(5):520-532. PubMed ID: 32134157
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of RND3/RhoE in glioblastoma patients promotes tumorigenesis through augmentation of notch transcriptional complex activity.
Liu B; Lin X; Yang X; Dong H; Yue X; Andrade KC; Guo Z; Yang J; Wu L; Zhu X; Zhang S; Tian D; Wang J; Cai Q; Chen Q; Mao S; Chen Q; Chang J
Cancer Med; 2015 Sep; 4(9):1404-16. PubMed ID: 26108681
[TBL] [Abstract][Full Text] [Related]
15. FHL2 interacts with EGFR to promote glioblastoma growth.
Sun L; Yu S; Xu H; Zheng Y; Lin J; Wu M; Wang J; Wang A; Lan Q; Furnari F; Cavenee W; Purow B; Li M
Oncogene; 2018 Mar; 37(10):1386-1398. PubMed ID: 29321665
[TBL] [Abstract][Full Text] [Related]
16. YTHDF2 facilitates UBXN1 mRNA decay by recognizing METTL3-mediated m
Chai RC; Chang YZ; Chang X; Pang B; An SY; Zhang KN; Chang YH; Jiang T; Wang YZ
J Hematol Oncol; 2021 Jul; 14(1):109. PubMed ID: 34246306
[TBL] [Abstract][Full Text] [Related]
17. TRIM11 is overexpressed in high-grade gliomas and promotes proliferation, invasion, migration and glial tumor growth.
Di K; Linskey ME; Bota DA
Oncogene; 2013 Oct; 32(42):5038-47. PubMed ID: 23178488
[TBL] [Abstract][Full Text] [Related]
18. PDRG1 promotes the proliferation and migration of GBM cells by the MEK/ERK/CD44 pathway.
Sun J; Xu Y; Liu J; Cui H; Cao H; Ren J
Cancer Sci; 2022 Feb; 113(2):500-516. PubMed ID: 34812552
[TBL] [Abstract][Full Text] [Related]
19. The role of PTRF/Cavin1 as a biomarker in both glioma and serum exosomes.
Huang K; Fang C; Yi K; Liu X; Qi H; Tan Y; Zhou J; Li Y; Liu M; Zhang Y; Yang J; Zhang J; Li M; Kang C
Theranostics; 2018; 8(6):1540-1557. PubMed ID: 29556340
[TBL] [Abstract][Full Text] [Related]
20. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
